Abstract:Type I interferons (T1-IFN) are critical in the innate immune response, acting upon infected and uninfected cells to initiate an antiviral state by expressing genes that inhibit multiple stages of the lifecycle of many viruses. T1-IFN triggers the production of Interferon-Stimulated Genes (ISGs), activating an antiviral program that reduces virus replication. The importance of the T1-IFN response is highlighted by the evolution of viral evasion strategies to inhibit the production or action of T1-IFN in virus-infected cells. T1-IFN is produced via activation of pathogen sensors within infected cells, a process that is targeted by virus-encoded immunomodulatory molecules. This is probably best exemplified by the prototypic poxvirus, Vaccinia virus (VACV), which uses at least 6 different mechanisms to completely block the production of T1-IFN within infected cells in vitro. Yet, mice lacking aspects of T1-IFN signaling are often more susceptible to infection with many viruses, including VACV, than wild-type mice. How can these opposing findings be rationalized? The cytosolic DNA sensor cGAS has been implicated in immunity to VACV, but has yet to be linked to the production of T1-IFN in response to VACV infection. Indeed, there are two VACV-encoded proteins that effectively prevent cGAS-mediated activation of T1-IFN. We find that the majority of VACV-infected cells in vivo do not produce T1-IFN, but that a small subset of VACV-infected cells in vivo utilize cGAS to sense VACV and produce T1-IFN to protect infected mice. The protective effect of T1-IFN is not mediated via ISG-mediated control of virus replication. Rather, T1-IFN drives increased expression of CCL4, which recruits inflammatory monocytes that constrain the VACV lesion in a virus replication-independent manner by limiting spread within the tissue. Our findings have broad implications in our understanding of pathogen detection and viral evasion in vivo, and highlight a novel immune strategy to protect infected tissue.

Apoptotic Caspases Suppress Type I Interferon Production Via the Cleavage of Cgas, MAVS, and IRF3.

Inflammasome Activation Triggers Caspase-1-Mediated Cleavage of Cgas to Regulate Responses to Dna Virus Infection

Noncanonical NF-κB Pathway Controls the Production of Type I Interferons in Antiviral Innate Immunity

XAF1 Protects Host Against RNA Viruses&nbsp;by Stabilizing IRF1-Dependent Antiviral Immunity

Single-nucleotide methylation specifically represses type I interferon in antiviral innate immunity

NBR1 Mediates Autophagic Degradation of IRF3 to Negatively Regulate Type I Interferon Production.

Caspases Control Antiviral Innate Immunity

Temporal regulation of MDA5 inactivation by Caspase-3 dependent cleavage of 14-3-3η

Apoptotic caspase inhibits innate immune signaling by cleaving NF-κBs in both Mammals and Flies

Molecular mechanism of RIPK1 and caspase-8 in homeostatic type I interferon production and regulation

Influenza A virus infection activates caspase-8 to enhance innate antiviral immunity by cleaving CYLD and blocking TAK1 and RIG-I deubiquitination

Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression

DDX3X Coordinates Host Defense Against Influenza Virus by Activating the NLRP3 Inflammasome and Type I Interferon Response

Apoptotic caspases cleave DRP1 to promote mitochondrial fusion and anti-viral immune responses

Caspase-8 restricts antiviral CD8 T cell hyperaccumulation

Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis.

Type I interferon-dependent CCL4 is induced by a cGAS/STING pathway that bypasses viral inhibition and protects infected tissue, independent of viral burden

The IFN‐inducible GTPase IRGB10 Regulates Viral Replication and Inflammasome Activation During Influenza A Virus Infection in Mice

Coronaviruses using different strategies to antagonize antiviral responses and pyroptosis

Negative regulation of MAVS-mediated innate immune response by ASC

Genome-Wide CRISPR/Cas9 Screening Identifies That Mitochondrial Solute Carrier SLC25A23 Attenuates Type I IFN Antiviral Immunity Via Interfering with MAVS Aggregation.